Avexa (AVX)

Stock Code

AVX

Stock Exchange

Australian Securities Exchange

Avexa (AVX) is a drug-discovery company principally engaged in the research and development of anti-infectives. Avexa's core focus is on the research, discovery and development of innovative medicines for the cure of the diseases caused by Human Immunodeficiency Virus (HIV) and Vancomycin- and methicillin-resistant bacteria. Avexa listed on the Australian Stock Exchange on 23rd September, 2004 and it is headquartered in Melbourne, Victoria. During 2008 the principal activities of the Company were the conduction of anti-infective pharmaceutical programs and projects. The Company commenced a Phase III development program for apricitabine (ATC) during the fiscal year ended 30 June, 2008, with positive data obtained from the 48-week Phase IIb study for ATC. Avexa has also progressed its HIV integrase and antibacterial projects towards pre-clinical studies during fiscal 2008. Avexa has created numerous small molecules in its Integrase program that help in slowing down the HIV infection of cells. Avexa has an alliance with TargetDrug of Shanghai for the development of small molecule inhibitors of hepatitis C virus (HCV). The Company is also actively involved in the development of AVX754, a compound for use in HIV treatment through a licence agreement with Shire Biochem Inc, with a focus on progressing this project into clinical development.